Genomic characterization of metastatic breast cancers
暂无分享,去创建一个
Yahia Adnani | Thomas Bachelot | Florence Dalenc | Thomas Filleron | Daniel Birnbaum | Salvatore Piscuoglio | Maud Kamal | Christophe Le Tourneau | Fabrice André | François Bertucci | Mario Campone | F. Bertucci | D. Birnbaum | F. André | H. Bonnefoi | M. Campone | J. Soria | N. Droin | F. Dalenc | T. Bachelot | G. Meurice | M. Kamal | C. Ng | M. Filippo | T. Filleron | M. D. De Filippo | S. Piscuoglio | Guillaume Meurice | N. Carbuccia | M. Chaffanet | Nathalie Droin | Max Chaffanet | Naveen Babbar | Jean Charles Soria | Claudia Lefeuvre | Marta Jimenez | B. Verret | Charlotte K. Y. Ng | A. Patsouris | A. T. Dien | Yahia Adnani | S. Garnier | M. Jimenez | S. Dogan | C. Lefeuvre | A. Jacquet | N. Babbar | C. Tourneau | Nadine Carbuccia | Anne Patsouris | Alicia Tran Dien | Séverine Garnier | Semih Dogan | Benjamin Verret | Herve Bonnefoi | Alexandra Jacquet | Maria R. De Filippo | C. le Tourneau | Y. Adnani | J. Soria
[1] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .
[2] F. Couch,et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.
[3] J. Reis-Filho,et al. Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases , 2018, Oncotarget.
[4] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[5] L. Chow,et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. , 2018, The Lancet. Oncology.
[6] Nicolas Servant,et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.
[7] Reuben S Harris,et al. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer , 2016, Science Advances.
[8] C. Sotiriou,et al. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] A. Bouchard-Côté,et al. PyClone: statistical inference of clonal population structure in cancer , 2014, Nature Methods.
[10] M. Heinrich,et al. Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors , 2009, Clinical Cancer Research.
[11] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[12] J. Reis-Filho,et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes , 2017, Nature Communications.
[13] A. Viale,et al. Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma , 2018, Clinical Cancer Research.
[14] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[15] C. Sander,et al. 3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets , 2017, Genome Medicine.
[16] Trevor J Pugh,et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation , 2013, Nucleic acids research.
[17] A. Vincent-Salomon,et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.
[18] Ronglai Shen,et al. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. , 2018, Cancer cell.
[19] E. Legius,et al. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. , 2016, The Journal of clinical investigation.
[20] D. Mathews,et al. Pyrvinium pamoate changes alternative splicing of the serotonin receptor 2C by influencing its RNA structure , 2013, Nucleic acids research.
[21] N. Socci,et al. Accelerating Discovery of Functional Mutant Alleles in Cancer. , 2018, Cancer discovery.
[22] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[23] P. Lønning,et al. Genomic Evolution of Breast Cancer Metastasis and Relapse , 2017, Cancer cell.
[24] Carlos Caldas,et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer , 2015, Nature Communications.
[25] T. Speed,et al. Correction: The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE" , 2017, PLoS medicine.
[26] B. Taylor,et al. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.
[27] P. V. van Diest,et al. Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. , 2018, Cancer research.
[28] William Pao,et al. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.
[29] Ash A. Alizadeh,et al. Integrated digital error suppression for improved detection of circulating tumor DNA , 2016, Nature Biotechnology.
[30] Jean Y. J. Wang,et al. Targeting the RB-pathway in Cancer Therapy , 2010, Clinical Cancer Research.
[31] N. Navin,et al. Clonal Evolution in Breast Cancer Revealed by Single Nucleus Genome Sequencing , 2014, Nature.
[32] Robert T. Jones,et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.
[33] Lajos Pusztai,et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations , 2017, Nature Communications.
[34] E. Lander,et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.
[35] Alessandro Pastore,et al. KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function , 2018, Oncogene.
[36] Javed Siddiqui,et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.
[37] Wendy S. W. Wong,et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..
[38] Jan Schröder,et al. Socrates: identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads , 2014, Bioinform..
[39] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[40] J. Troge,et al. Tumour evolution inferred by single-cell sequencing , 2011, Nature.
[41] V. Seshan,et al. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.
[42] Jorge S. Reis-Filho,et al. Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.
[43] A. Regev,et al. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies , 2018, Nature Genetics.
[44] Benjamin J. Raphael,et al. CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer , 2015, Genome Biology.
[45] A. Viale,et al. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases , 2017, Clinical Cancer Research.
[46] E. Mardis,et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens , 2016, Genome Medicine.
[47] B. Taylor,et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.
[48] Marie-Cécile Le Deley,et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.
[49] Thomas Bachelot,et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.
[50] Melissa P. Murray,et al. The Genomic Landscape of Male Breast Cancers , 2016, Clinical Cancer Research.
[51] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[52] P. Fasching,et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] C. Lefebvre,et al. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis , 2016, PLoS medicine.
[54] E. Winer,et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.
[55] Kai Ye,et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..
[56] Kun Yu,et al. PureCN: copy number calling and SNV classification using targeted short read sequencing , 2016, Source Code for Biology and Medicine.
[57] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[58] Nicolai J. Birkbak,et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.